Aeolus Pharmaceuticals to Present at Oppenheimer 21st Annual Healthcare Conference Read more: http://www.financialpost.com/markets/news/Aeolus+Pharma

Aeolus Pharmaceuticals, Inc. ( today announced that it will be presenting at the Oppenheimer 21st Annual Healthcare Conference at 9:40 a.m. ET on Tuesday, November 2, 2010, in the Louis XVI Room at the Waldorf-Astoria Hotel in New York City, NY. The Company plans to provide a corporate summary and update on the Company's progress.

Aeolus will also host one-on-one meetings with members of the professional community in New York on November 2-3, 2010. Professional investors can schedule a meeting with the Company by contacting Russell Skibsted at (949) 481-9821 or by scheduling a meeting through the one-on-one desk at Oppenheimer. Those investors attending the conference are encouraged to sign up to meet with the Company at the conference through their Oppenheimer sales representative.

Over more than 20 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in life science sector. The conference will include a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries.

Aeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds that protects healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Government, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus’ strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to efficiently develop the compound for use in oncology.

Aeolus Pharmaceuticals Submits White Paper to BARDA for Funding of AEOL 10150 as a Countermeasure to Lung Injury Due to Radiation Exposure

Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced today that it has submitted a white paper to the Biomedical Advanced Research and Development Authority (BARDA) in response to Special Instructions Amendment 4 to a Broad Agency Announcement (BAA-BARDA-09-34) for advanced research and development of medical countermeasures for chemical, biological, radiological and nuclear threats. The purpose of the special instructions amendment is to specifically solicit solutions for treating cutaneous and/or pulmonary (life-threatening pneumonitis and fibrosis) injuries resulting from exposure to ionizing radiation. BARDA is interested in advanced development and eventual licensure/approval of medical countermeasures for cutaneous and/or pulmonary injuries resulting from an acute exposure to radiation from a radiological/nuclear accident or attack, particularly injuries associated with Acute Radiation Syndrome (ARS) or Delayed Effects of Acute Radiation Exposure (DEARE).

BARDA is seeking safe and effective medical countermeasures that mitigate, treat, affect, delay, or interrupt the progression of cutaneous and/or pulmonary injury caused by ionizing radiation. Aeolus is requesting funding to further develop AEOL 10150 for the treatment and prevention of such pulmonary injuries, including pneumonitis and fibrosis. In animal studies, AEOL 10150 has demonstrated an ability to protect lung tissue against fibrosis, reduce mortality and maintain normal body weights when administered between 2 hours to 24 hours after exposure. Ongoing studies will examine how far beyond the 24-hour window the compound can be administered and still be effective. AEOL 10150 is also being tested by the National Institutes for Health, National Institute for Allergies and Immunological Disorders, Medical Countermeasures Against

Radiological Threats (NIH/NIAID/MCART) as a countermeasure against radiation exposure of the Gastro-intestinal system (ARS-GI).

"We look forward to BARDA's decision regarding our white paper for the advanced development of AEOL 10150. Our compound has demonstrated safety in phase 1 human studies and efficacy in animal studies when administered after radiation exposure, and this potential funding could allow us to complete the development of the compound and file an NDA for approval by the FDA," stated John L. McManus, President & Chief Executive Officer of Aeolus Pharmaceuticals, Inc.